Leganes

• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 5 Uncontrolled Asthma
• Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and … Pending
  2025-521989-95-00 9 Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
• Optimizing Aspirin Use for Preeclampsia Prevention Pending
  2025-524646-94-00 11 Obstetrics – Preeclampsia
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A Study of YL201 in Patients With Advanced Solid Tumors Recruiting
  2024-517589-41-00 1 2025-08-04 Advanced solid tumors
• Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting
  2024-518812-38-00 4 2025-07-02 Non-small cell lung cancer (NSCLC)
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) versus Conventional Treatment in Acute Myocarditis: INFLAMA study Recruiting
  2024-513803-15-00 6 2025-01-30 Acute myocarditis
• COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE Recruiting
  2023-505868-11-00 5 2025-01-17 CHRONIC RENAL DISEASE
• An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting
  2024-512161-14-00 3 2025-01-14 Breast Cancer
• A Randomized Clinical Trial, Multicentre, Open-label, Parallel-group, to define the best Strategy for the management of hEart failure aNd ch … Recruiting
  2024-513971-42-00 5 2024-10-01 Chronic heart failure (NYHA I-III) and non-dialysis CKD
• VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGN Recruiting
  2023-507293-40-00 6 2024-04-11 VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA
• A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting
  2024-513562-19-00 5 2023-08-30 End-Stage Kidney Disease
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 6 2018-01-10 Patients with invasive breast cancer in early stages
• Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer p … Ended recruitment
  2023-507438-25-00 2 2024-02-28 Non-small cell lung cancer
• Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam … Ended recruitment
  2023-507448-36-00 5 2024-02-16 Non-small Cell Lung Cancer
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
• A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA … Ended recruitment
  2024-511268-10-00 4 2022-05-25 Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cel
• Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE) Ended recruitment
  2023-504946-70-00 6 2021-12-01 Heart Failure
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk … Ended recruitment
  2023-505223-31-00 4 2019-06-14 Localized ER+ breast cancer
• A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended
  2022-502022-41-00 3 2024-05-28 Acute lower respiratory infection
• Safety and Immunogenicity of V116 in Children and Adolescents With Increased Risk for Pneumococcal Disease Ended
  2023-506236-32-00 5 2024-03-25 Pneumococcal disease
• A proof-of-concept study to examine QUC398 in participants with knee osteoarthritis Ended
  2023-509274-28-00 4 2023-02-03 Knee osteoarthritis

Showing 1–24 of 26 trials